Further large-scale randomized controlled trials will be necessary to confirm their efficacy in diverse populations and explore their impact on DNA fragmentation and live birth rates
Viking Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company, is advancing a dual GLP-1/GIP agonist, VK2735, for treating obesity for both subcutaneous and oral administration
Side effects are rare but may include mild skin irritation or redness
Spend time with loved ones
The GLP-1RA group also had a 32% higher risk of excess weight gain (gaining more than recommended), a 30% higher risk of diabetes during pregnancy, a 29% higher risk of hypertensive disorders during pregnancy, and a 34% higher risk of preterm delivery
This powerful antioxidant exists in two different forms, including the oxidized and reduced states